Yoshiyasu Minami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoshiyasu Minami has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Junya Ako
Department of Cardiovascular Medicine, Kitasato University School of Medicine
35 shared publicationsTakuya Hashimoto
20 shared publications- Ik-Kyung Jang
Cardiology Division, Massachusetts General Hospital—Harvard Medical School, Boston, MA 02114, USA
19 shared publications Takao Shimohama
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan
18 shared publicationsMasahiro Katamine
Department of Cardiovascular Medicine, Kitasato University School of Medicine
17 shared publicationsKentaro Meguro
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan
15 shared publications
Latest Publications
- 23 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- p. e020627
Polarimetric Imaging: In Search for Clinically Meaningful Vulnerability
- 23 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- p. e020627
Polarimetric Imaging: In Search for Clinically Meaningful Vulnerability
- Open Access
- 24 April 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (5) , 513-514
Not Just How Low, But How Stable ― Lipid Variability and Peripheral Artery Disease ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 24 April 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (5) , 513-514
Open AccessNot Just How Low, But How Stable ― Lipid Variability and Peripheral Artery Disease ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 12 March 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (8) , CJ-26-0092-998
From Measurement to Management ― Lipoprotein(a) After Acute Coronary Syndrome ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 12 March 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (8) , CJ-26-0092-998
Open AccessFrom Measurement to Management ― Lipoprotein(a) After Acute Coronary Syndrome ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 25 February 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (3) , 266-273
Global Low-Density Lipoprotein Cholesterol Targets for Patients With Acute Coronary Syndrome ― Current Guidelines and Clinical Pathways ―
The management of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease, particularly those with acute coronary syndrome (ACS), has evolved significantly. Recent evidence emphasizes the importance of early and intensive LDL-C lowering for reducing recurrent cardiovascular events by stabilizing vulnerable plaques. Global guidelines now advocate for more aggressive LDL-C targets, with a common recommendation of <55 mg/dL for high-risk ACS patients. However, regional variations persist in specific target levels, pharmacologic strategies, and follow-up schedules due to differences in healthcare infrastructure, epidemiology, and risk assessment frameworks. Despite guideline updates, achieving recommended LDL-C levels in real-world practice remains challenging, primarily due to issues like healthcare system limitations, patient adherence, and clinical inertia. Some regions in Japan have established local clinical pathways that demonstrate improvements in attainment of LDL-C targets and clinical outcomes. This article explores the current global LDL-C targets and treatment strategies for ACS patients, aiming to enhance the achievement of optimal LDL-C levels and reduce subsequent adverse events.
- 25 February 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (3) , 266-273
Open AccessGlobal Low-Density Lipoprotein Cholesterol Targets for Patients With Acute Coronary Syndrome ― Current Guidelines and Clinical Pathways ―
The management of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease, particularly those with acute coronary syndrome (ACS), has evolved significantly. Recent evidence emphasizes the importance of early and intensive LDL-C lowering for reducing recurrent cardiovascular events by stabilizing vulnerable plaques. Global guidelines now advocate for more aggressive LDL-C targets, with a common recommendation of <55 mg/dL for high-risk ACS patients. However, regional variations persist in specific target levels, pharmacologic strategies, and follow-up schedules due to differences in healthcare infrastructure, epidemiology, and risk assessment frameworks. Despite guideline updates, achieving recommended LDL-C levels in real-world practice remains challenging, primarily due to issues like healthcare system limitations, patient adherence, and clinical inertia. Some regions in Japan have established local clinical pathways that demonstrate improvements in attainment of LDL-C targets and clinical outcomes. This article explores the current global LDL-C targets and treatment strategies for ACS patients, aiming to enhance the achievement of optimal LDL-C levels and reduce subsequent adverse events.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 33 (1) , 1-12
High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease: The Pathophysiology, Prognosis, and Emerging Therapies
Inflammation plays a crucial role in the initiation, progression, and destabilization of atherosclerotic plaques and it contributes to recurrent cardiovascular events in patients with coronary artery disease (CAD). High-sensitivity C-reactive protein (hsCRP) is a well-established biomarker of systemic inflammation and it is a predictor of adverse outcomes, independent of low-density lipoprotein cholesterol (LDL-C) levels. Elevated hsCRP levels are consistently associated with higher event rates in both chronic and acute coronary syndromes, thus reflecting the residual inflammatory risk not addressed by lipid-lowering therapy or revascularization. Imaging studies have revealed that higher hsCRP levels correlate with a greater plaque burden and vulnerability. Recent trials have shown that anti-inflammatory therapies, including low-dose colchicine and interleukin-6 inhibition, can reduce this residual risk, while agents such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and bempedoic acid offer additional anti-inflammatory effects. The integration of anti-inflammatory strategies with intensive lipid management may thus provide additional cardiovascular benefits.
- 1 January 2026
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 33 (1) , 1-12
Top Cited PapersOpen AccessHigh-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease: The Pathophysiology, Prognosis, and Emerging Therapies
Inflammation plays a crucial role in the initiation, progression, and destabilization of atherosclerotic plaques and it contributes to recurrent cardiovascular events in patients with coronary artery disease (CAD). High-sensitivity C-reactive protein (hsCRP) is a well-established biomarker of systemic inflammation and it is a predictor of adverse outcomes, independent of low-density lipoprotein cholesterol (LDL-C) levels. Elevated hsCRP levels are consistently associated with higher event rates in both chronic and acute coronary syndromes, thus reflecting the residual inflammatory risk not addressed by lipid-lowering therapy or revascularization. Imaging studies have revealed that higher hsCRP levels correlate with a greater plaque burden and vulnerability. Recent trials have shown that anti-inflammatory therapies, including low-dose colchicine and interleukin-6 inhibition, can reduce this residual risk, while agents such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and bempedoic acid offer additional anti-inflammatory effects. The integration of anti-inflammatory strategies with intensive lipid management may thus provide additional cardiovascular benefits.
- Open Access
- 25 December 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (1) , 143
Coexistence of Calcification and Lipids: A Hidden Barrier to Optimal Stent Expansion
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 25 December 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (1) , 143
Open AccessCoexistence of Calcification and Lipids: A Hidden Barrier to Optimal Stent Expansion
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 23 November 2025
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 27
Increased macrophage activity in coronary plaques in patients with acute coronary syndrome and familial hypercholesterolemia
- 23 November 2025
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 27
Open AccessIncreased macrophage activity in coronary plaques in patients with acute coronary syndrome and familial hypercholesterolemia
- 12 October 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (1) , 11-28
Guide extension catheters in coronary intervention: device selection, technical insights, and clinical applications
Percutaneous coronary intervention (PCI) has evolved significantly with technological advances, allowing for higher procedural success rates and improved patient outcomes. However, the growing complexity of cases involving severely calcified lesions, tortuous vessels, and chronic total occlusions has increased procedural challenges. In such scenarios, the guide extension catheter (GEC, or guiding catheter extension) plays a critical role by enhancing device passage and providing additional backup support, making it indispensable in modern PCI. Various types of GECs offer distinct characteristics that influence their selection based on lesion type, device compatibility, and procedural requirements. The GEC is used for multiple purposes, including backup support, deep engagement, imaging device insertion, stent protection, thrombectomy, and foreign body removal. Despite its utility, GEC use is associated with potential complications, including vessel injury, thrombosis, air embolism, and hemodynamic instability. Careful technique and proper selection are critical to minimizing risks. Overall, the GEC is an essential tool in complex PCI procedures, offering significant advantages in improving procedural success. Graphical abstract Guide extension catheters in coronary intervention. GEC guide extension catheter, IVUS intravascular ultrasound, OAS orbital atherectomy, OCT optical coherence tomography, ROTA rotational atherectomy. Some of the methods shown involve off-label use; however, such use is not being recommended. Off-label use should be performed only by experienced operators and only when no alternative options are available in procedure. Always refer to the usage instructions.
- 12 October 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (1) , 11-28
Guide extension catheters in coronary intervention: device selection, technical insights, and clinical applications
Percutaneous coronary intervention (PCI) has evolved significantly with technological advances, allowing for higher procedural success rates and improved patient outcomes. However, the growing complexity of cases involving severely calcified lesions, tortuous vessels, and chronic total occlusions has increased procedural challenges. In such scenarios, the guide extension catheter (GEC, or guiding catheter extension) plays a critical role by enhancing device passage and providing additional backup support, making it indispensable in modern PCI. Various types of GECs offer distinct characteristics that influence their selection based on lesion type, device compatibility, and procedural requirements. The GEC is used for multiple purposes, including backup support, deep engagement, imaging device insertion, stent protection, thrombectomy, and foreign body removal. Despite its utility, GEC use is associated with potential complications, including vessel injury, thrombosis, air embolism, and hemodynamic instability. Careful technique and proper selection are critical to minimizing risks. Overall, the GEC is an essential tool in complex PCI procedures, offering significant advantages in improving procedural success. Graphical abstract Guide extension catheters in coronary intervention. GEC guide extension catheter, IVUS intravascular ultrasound, OAS orbital atherectomy, OCT optical coherence tomography, ROTA rotational atherectomy. Some of the methods shown involve off-label use; however, such use is not being recommended. Off-label use should be performed only by experienced operators and only when no alternative options are available in procedure. Always refer to the usage instructions.
- Open Access
- 25 July 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 89 (8) , 1096-1103
Current Status and Prospects of Regional Collaborative Pathways for Management of Acute Coronary Syndrome in Japan ― A Nationwide Survey ―
Background: Comprehensive management of acute coronary syndrome (ACS) requires seamless treatment across institutions, including intensive care centers and local clinics. However, maintaining guideline-directed medical therapy remains challenging. One promising option to improve the situation may be the implementation of regional collaborative clinical pathways. This study evaluated the prevalence and functionality of such pathways for ACS in Japan.Methods and Results: A nationwide survey was conducted through questionnaires and web searches, targeting all 47 prefectural managers of Japanese Circulation Association (JCA) branches. The study focused on pathways managed at the prefectural or regional levels, excluding inactive or institutional pathways. In all, 18 pathways were identified: 11 (23%) prefecture wide and 4 (9%) region wide. Most pathways included risk factor targets such as low-density lipoprotein cholesterol (LDL-C), HbA1c, and blood pressure, but only 8 pathways set an LDL-C target of <70 mg/dL. Pathways updated between 2022 and 2024 and incorporating LDL-C management protocols were considered functional. In all, 45 JCA branches viewed future ACS pathways established by the government or academic societies as potentially useful resources.Conclusions: Regional collaborative clinical pathways for ACS patients in Japan show variable implementation across prefectures, with approximately one-third of prefectures having established pathways. Future efforts should prioritize the establishment of comprehensive, sustainable, and standardized pathways to optimize ACS management and improve patient outcomes nationwide.
- 25 July 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 89 (8) , 1096-1103
Open AccessCurrent Status and Prospects of Regional Collaborative Pathways for Management of Acute Coronary Syndrome in Japan ― A Nationwide Survey ―
Background: Comprehensive management of acute coronary syndrome (ACS) requires seamless treatment across institutions, including intensive care centers and local clinics. However, maintaining guideline-directed medical therapy remains challenging. One promising option to improve the situation may be the implementation of regional collaborative clinical pathways. This study evaluated the prevalence and functionality of such pathways for ACS in Japan.Methods and Results: A nationwide survey was conducted through questionnaires and web searches, targeting all 47 prefectural managers of Japanese Circulation Association (JCA) branches. The study focused on pathways managed at the prefectural or regional levels, excluding inactive or institutional pathways. In all, 18 pathways were identified: 11 (23%) prefecture wide and 4 (9%) region wide. Most pathways included risk factor targets such as low-density lipoprotein cholesterol (LDL-C), HbA1c, and blood pressure, but only 8 pathways set an LDL-C target of <70 mg/dL. Pathways updated between 2022 and 2024 and incorporating LDL-C management protocols were considered functional. In all, 45 JCA branches viewed future ACS pathways established by the government or academic societies as potentially useful resources.Conclusions: Regional collaborative clinical pathways for ACS patients in Japan show variable implementation across prefectures, with approximately one-third of prefectures having established pathways. Future efforts should prioritize the establishment of comprehensive, sustainable, and standardized pathways to optimize ACS management and improve patient outcomes nationwide.
- Open Access
- 24 April 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (4) , e70137
The Role of Esaxerenone in the Continuum of Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Observational Study
Background: Heart failure with preserved ejection fraction (HFpEF) presents significant therapeutic challenges, particularly exacerbated by comorbidities such as hypertension and diabetes. The modulation of the Renin–Angiotensin–Aldosterone System is critical in managing HFpEF progression. Esaxerenone (ESAX), a selective mineralocorticoid receptor antagonist, may offer benefits in managing HFpEF continuum due to its unique mechanism.Methods: Conducted at Odawara Municipal Hospital, this single‐center, prospective, observational study involved hypertensive adult outpatients diagnosed with either type 2 diabetes mellitus or chronic kidney disease. Patients were categorized into HFpEF and pre‐HFpEF groups based on established criteria. The study primarily assessed changes in blood pressure and cardiac function (through NT‐proBNP levels and echocardiography), along with secondary outcomes including aortic stiffness and oxidative stress over a 24‐week period.Results: Both HFpEF and pre‐HFpEF patients exhibited significant reductions in blood pressure, with no significant differences between the patients. HFpEF patients experienced decreases in NT‐proBNP levels and oxidative stress similar to those in pre‐HFpEF patients. Notably, pre‐HFpEF patients demonstrated more pronounced improvements in cardiac function, particularly in the E/e' ratio and global longitudinal strain, compared to HFpEF patients. Additionally, 30% of pre‐HFpEF patients had improved to stage A, suggesting potential for early intervention.Conclusions: ESAX appears to be effective in managing the heart failure continuum, particularly benefiting pre‐HFpEF patients. Its impacts suggest the potential benefits of early intervention in decelerating disease progression and potentially preventing the new onset of HFpEF, highlighting the importance of targeted therapies at early stages of heart failure.
- 24 April 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (4) , e70137
Open AccessThe Role of Esaxerenone in the Continuum of Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Observational Study
Background: Heart failure with preserved ejection fraction (HFpEF) presents significant therapeutic challenges, particularly exacerbated by comorbidities such as hypertension and diabetes. The modulation of the Renin–Angiotensin–Aldosterone System is critical in managing HFpEF progression. Esaxerenone (ESAX), a selective mineralocorticoid receptor antagonist, may offer benefits in managing HFpEF continuum due to its unique mechanism.Methods: Conducted at Odawara Municipal Hospital, this single‐center, prospective, observational study involved hypertensive adult outpatients diagnosed with either type 2 diabetes mellitus or chronic kidney disease. Patients were categorized into HFpEF and pre‐HFpEF groups based on established criteria. The study primarily assessed changes in blood pressure and cardiac function (through NT‐proBNP levels and echocardiography), along with secondary outcomes including aortic stiffness and oxidative stress over a 24‐week period.Results: Both HFpEF and pre‐HFpEF patients exhibited significant reductions in blood pressure, with no significant differences between the patients. HFpEF patients experienced decreases in NT‐proBNP levels and oxidative stress similar to those in pre‐HFpEF patients. Notably, pre‐HFpEF patients demonstrated more pronounced improvements in cardiac function, particularly in the E/e' ratio and global longitudinal strain, compared to HFpEF patients. Additionally, 30% of pre‐HFpEF patients had improved to stage A, suggesting potential for early intervention.Conclusions: ESAX appears to be effective in managing the heart failure continuum, particularly benefiting pre‐HFpEF patients. Its impacts suggest the potential benefits of early intervention in decelerating disease progression and potentially preventing the new onset of HFpEF, highlighting the importance of targeted therapies at early stages of heart failure.